Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesMemantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Clinical Interventions in Aging, 09/28/09
Thomas SJ et al. – Memantine is an uncompetitive N–methyl–D–aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.
Related Articles
Benefit Of Memantine In The Treatment Of Alzheimers Disease Not Proven
ScienceDaily, 10/29/09
Relevance Score: 66%
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy
European Journal of Neurology, 11/03/09
Relevance Score: 65%
Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer’s disease
Neuropsychiatric Disease and Treatment, 11/04/09
Relevance Score: 64%
Variability in the Prescription of Cholinesterase Inhibitors and Memantine
Dementia and Geriatric Cognitive Disorders, 11/03/09
Relevance Score: 64%
Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008
BMC Neurology, 10/23/09
Relevance Score: 47%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of Methylphenidate on Cerebral Glucose Metabolism in Patients With Impaired Consciousness After Acquired Brain Injury
Clinical Neuropharmacology, 12/05/09
Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Neuropharmacology, 12/05/09
Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP
Epilepsia, 12/05/09
Sponsor
Article Search
Sponsor